The recent ESMO 2024 data highlighted significant advancements in immunotherapy. Check out the results from Merck, BMY, ...

Study Meets Overall Response Rate Primary Endpoint, Encouraging Secondary Endpoint Progression-Free Survival Data in Squamous Cell Carcinoma ...

The poster can be found on the “Posters ... IO Biotech is sponsoring the Phase 2 trial and Merck is supplying pembrolizumab. IO Biotech maintains global commercial rights to IO102-IO103.

Overall survival (OS) data for KEYTRUDA ® (pembrolizumab) in earlier stages of women’s cancers, including high-risk early-stage triple-negative breast cancer (KEYNOTE-522) and high-risk locally ...

The ESMO Proferred Paper Oral Presentation slides are available on the Posters & Publications ... in combination with MSD’s ...

Cytovation to present safety and efficacy data from CICILIA phase I/IIa clinical trial evaluating CY-101 in solid tumors: Bergen, Norway Monday, September 16, 2024, 18:00 Hrs [IST ...

plus pembrolizumab (KEYTRUDA®), the anti-PD-1 therapy from Merck & Co., Inc., Kenilworth, in combination withtransarterial chemoembolization (TACE) for the treatment of patients with unresectable ...

Danish clinical-stage techbio firm Evaxion Biotech,which is developing AI-Immunology powered vaccines, announced new clinical ...

Three partial responses (PR) and one stable disease (SD) out of four evaluable patients with Cutaneous T-cell Lymphoma (CTCL) have been observed in the single agent part of the Phase 2a study. Three ...